Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02920177 · ClinicalTrials.gov registry record · Phase 4
Platelet-rich Plasma Versus Corticosteroid Injection for the Treatment of Femoroacetabular Impingement
A Phase 4 study, sponsored by University of Michigan.
- Terminated
- Registry status
- Phase 4
- Development phase
- 4
- Enrollment target
NCT02920177 is a Phase 4 study that was terminated before completion, run by University of Michigan. The registered enrollment target is 4 participants.
The verdict
NCT02920177, a Phase 4 study, was terminated before completion, sponsored by University of Michigan.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 4 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the clinical response of intra-articular platelet rich plasma (PRP) versus corticosteroid injection in patients affected by femoroacetabular impingement (FAI).
Interventions
- DRUG platelet-rich plasma injection
- DRUG Kenalog 10 MG/ML Injectable Suspension
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2016-08-01 |
| Est. Completion | 2018-08-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02920177
The ClinicalTrials.gov registry entry for NCT02920177 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan, which has 1,327 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which platelet-rich plasma injection is the first listed.
NCT02920177 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02920177 about?
NCT02920177 is a clinical study titled "Platelet-rich Plasma Versus Corticosteroid Injection for the Treatment of Femoroacetabular Impingement". The purpose of this study is to compare the clinical response of intra-articular platelet rich plasma (PRP) versus corticosteroid injection in patients affected by femoroacetabular impingement (FAI).
What is the current status of trial NCT02920177?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 4 participants. The study started on 2016-08-01. Estimated completion is 2018-08-10.
What interventions are being tested in trial NCT02920177?
The interventions under investigation include: platelet-rich plasma injection (DRUG), Kenalog 10 MG/ML Injectable Suspension (DRUG).
Who is sponsoring clinical trial NCT02920177?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.